Evidence for Effective Multiple K+-Current Inhibitions by Tolvaptan, a Non-peptide Antagonist of Vasopressin V2 Receptor

Tolvaptan (TLV), an oral non-peptide antagonist of vasopressin V2 receptor, has been increasingly used for managements in patients with hyponatremia and/or syndrome of inappropriate antidiuretic hormone secretion. However, none of the studies have thus far been investigated with regard to its possib...

Full description

Bibliographic Details
Main Authors: Te-Ling Lu, Wei-Ting Chang, Chee-Hong Chan, Sheng-Nan Wu
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-02-01
Series:Frontiers in Pharmacology
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2019.00076/full
id doaj-55a944659eee4d8699dde1b9d0cbb56f
record_format Article
spelling doaj-55a944659eee4d8699dde1b9d0cbb56f2020-11-24T21:43:39ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122019-02-011010.3389/fphar.2019.00076439572Evidence for Effective Multiple K+-Current Inhibitions by Tolvaptan, a Non-peptide Antagonist of Vasopressin V2 ReceptorTe-Ling Lu0Wei-Ting Chang1Chee-Hong Chan2Sheng-Nan Wu3Sheng-Nan Wu4School of Pharmacy, China Medical University, Taichung, TaiwanDivision of Cardiovascular Medicine, Chi-Mei Medical Center, Tainan, TaiwanDepartment of Nephrology, Chang Bing Show Chwan Memorial Hospital, Changhua, TaiwanDepartment of Physiology, National Cheng Kung University Medical College, Tainan, TaiwanInstitute of Basic Medical Sciences, National Cheng Kung University Medical College, Tainan, TaiwanTolvaptan (TLV), an oral non-peptide antagonist of vasopressin V2 receptor, has been increasingly used for managements in patients with hyponatremia and/or syndrome of inappropriate antidiuretic hormone secretion. However, none of the studies have thus far been investigated with regard to its possible perturbations on membrane ion currents in endocrine or neuroendocrine cells. In our electrophysiological study, the whole-cell current recordings showed that the presence of TLV effectively and differentially suppressed the amplitude of delayed rectifier K+ (IK(DR)) and M-type K+ current (IK(M)) in pituitary GH3 cells with an IC50 value of 6.42 and 1.91 μM, respectively. This compound was also capable of shifting the steady-state activation curve of IK(M) to less depolarized potential without any appreciable change in the gating charge of this current. TLV at a concentration greater than 10 μM also suppressed the amplitude of erg-mediated K+ current or the activity of large-conductance Ca2+-activated K+ channels; however, this compound failed to alter the amplitude of hyperpolarization-activated cation current in GH3 cells. In vasopressin-preincubated GH3 cells, TLV-mediated suppression of IK(M) remained little altered. Under current-clamp condition, we also observed that addition of TLV increased the firing of spontaneous action potentials in GH3 cells and further addition of flupirtine could reverse TLV-mediated elevation of the firing. In Madin-Darby canine kidney (MDCK) cells, the K+ current elicited by long ramp pulse was also effectively subject to inhibition by this compound. Findings from the present study were thus stated as saying that the suppression by TLV of multiple type K+ currents could be direct and independent of its antagonism of vasopressin V2 receptors. Our study also reveals an important aspect that should be considered when assessing aquaretic effect of TLV or its structurally similar compounds.https://www.frontiersin.org/article/10.3389/fphar.2019.00076/fulltolvaptanM-type K+ currentdelayed-rectifier K+ currenterg-mediated K+ currentmembrane potentialpituitary cell
collection DOAJ
language English
format Article
sources DOAJ
author Te-Ling Lu
Wei-Ting Chang
Chee-Hong Chan
Sheng-Nan Wu
Sheng-Nan Wu
spellingShingle Te-Ling Lu
Wei-Ting Chang
Chee-Hong Chan
Sheng-Nan Wu
Sheng-Nan Wu
Evidence for Effective Multiple K+-Current Inhibitions by Tolvaptan, a Non-peptide Antagonist of Vasopressin V2 Receptor
Frontiers in Pharmacology
tolvaptan
M-type K+ current
delayed-rectifier K+ current
erg-mediated K+ current
membrane potential
pituitary cell
author_facet Te-Ling Lu
Wei-Ting Chang
Chee-Hong Chan
Sheng-Nan Wu
Sheng-Nan Wu
author_sort Te-Ling Lu
title Evidence for Effective Multiple K+-Current Inhibitions by Tolvaptan, a Non-peptide Antagonist of Vasopressin V2 Receptor
title_short Evidence for Effective Multiple K+-Current Inhibitions by Tolvaptan, a Non-peptide Antagonist of Vasopressin V2 Receptor
title_full Evidence for Effective Multiple K+-Current Inhibitions by Tolvaptan, a Non-peptide Antagonist of Vasopressin V2 Receptor
title_fullStr Evidence for Effective Multiple K+-Current Inhibitions by Tolvaptan, a Non-peptide Antagonist of Vasopressin V2 Receptor
title_full_unstemmed Evidence for Effective Multiple K+-Current Inhibitions by Tolvaptan, a Non-peptide Antagonist of Vasopressin V2 Receptor
title_sort evidence for effective multiple k+-current inhibitions by tolvaptan, a non-peptide antagonist of vasopressin v2 receptor
publisher Frontiers Media S.A.
series Frontiers in Pharmacology
issn 1663-9812
publishDate 2019-02-01
description Tolvaptan (TLV), an oral non-peptide antagonist of vasopressin V2 receptor, has been increasingly used for managements in patients with hyponatremia and/or syndrome of inappropriate antidiuretic hormone secretion. However, none of the studies have thus far been investigated with regard to its possible perturbations on membrane ion currents in endocrine or neuroendocrine cells. In our electrophysiological study, the whole-cell current recordings showed that the presence of TLV effectively and differentially suppressed the amplitude of delayed rectifier K+ (IK(DR)) and M-type K+ current (IK(M)) in pituitary GH3 cells with an IC50 value of 6.42 and 1.91 μM, respectively. This compound was also capable of shifting the steady-state activation curve of IK(M) to less depolarized potential without any appreciable change in the gating charge of this current. TLV at a concentration greater than 10 μM also suppressed the amplitude of erg-mediated K+ current or the activity of large-conductance Ca2+-activated K+ channels; however, this compound failed to alter the amplitude of hyperpolarization-activated cation current in GH3 cells. In vasopressin-preincubated GH3 cells, TLV-mediated suppression of IK(M) remained little altered. Under current-clamp condition, we also observed that addition of TLV increased the firing of spontaneous action potentials in GH3 cells and further addition of flupirtine could reverse TLV-mediated elevation of the firing. In Madin-Darby canine kidney (MDCK) cells, the K+ current elicited by long ramp pulse was also effectively subject to inhibition by this compound. Findings from the present study were thus stated as saying that the suppression by TLV of multiple type K+ currents could be direct and independent of its antagonism of vasopressin V2 receptors. Our study also reveals an important aspect that should be considered when assessing aquaretic effect of TLV or its structurally similar compounds.
topic tolvaptan
M-type K+ current
delayed-rectifier K+ current
erg-mediated K+ current
membrane potential
pituitary cell
url https://www.frontiersin.org/article/10.3389/fphar.2019.00076/full
work_keys_str_mv AT telinglu evidenceforeffectivemultiplekcurrentinhibitionsbytolvaptananonpeptideantagonistofvasopressinv2receptor
AT weitingchang evidenceforeffectivemultiplekcurrentinhibitionsbytolvaptananonpeptideantagonistofvasopressinv2receptor
AT cheehongchan evidenceforeffectivemultiplekcurrentinhibitionsbytolvaptananonpeptideantagonistofvasopressinv2receptor
AT shengnanwu evidenceforeffectivemultiplekcurrentinhibitionsbytolvaptananonpeptideantagonistofvasopressinv2receptor
AT shengnanwu evidenceforeffectivemultiplekcurrentinhibitionsbytolvaptananonpeptideantagonistofvasopressinv2receptor
_version_ 1725912811326930944